Abstract
The efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with human immunodeficiency virus (HIV) and/or genotype 3 hepatitis C virus (HCV) infection is yet to be clarified. This is because no or only a few patients have been included in Japanese phase 3 trials. We herein report for the first time the successful treatment of glecaprevir and pibrentasvir in three Japanese patients with HIV and genotype 3 HCV coinfection as well as hemophilia. Glecaprevir and pibrentasvir treatment is safe and effective for Japanese patients with genotype 3 HCV and HIV coinfection.
Keywords:
HCV; HIV; genotype 3; glecaprevir; hemophilia; pibrentasvir.
MeSH terms
-
Aminoisobutyric Acids
-
Antiviral Agents / therapeutic use*
-
Benzimidazoles / therapeutic use*
-
Coinfection / drug therapy*
-
Cyclopropanes
-
Drug Therapy, Combination
-
Genotype
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV-1*
-
Hepacivirus / genetics
-
Hepatitis C, Chronic / complications
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / virology
-
Humans
-
Lactams, Macrocyclic
-
Leucine / analogs & derivatives
-
Male
-
Middle Aged
-
Proline / analogs & derivatives
-
Pyrrolidines
-
Quinoxalines / therapeutic use*
-
Sulfonamides / therapeutic use*
Substances
-
Aminoisobutyric Acids
-
Antiviral Agents
-
Benzimidazoles
-
Cyclopropanes
-
Lactams, Macrocyclic
-
Pyrrolidines
-
Quinoxalines
-
Sulfonamides
-
pibrentasvir
-
Proline
-
Leucine
-
glecaprevir